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Background. We introduce the Gene Characterization Index, a bioinformatics method for scoring the extent to which a protein-
encoding gene is functionally described. Inherently a reflection of human perception, the Gene Characterization Index is applied
for assessing the characterization status of individual genes, thus serving the advancement of both genome annotation and
applied genomics research by rapid and unbiased identification of groups of uncharacterized genes for diverse applications such
asdirectedfunctional studiesanddelineation ofnoveldrugtargets. Methodology/PrincipalFindings. Thescoringprocedureis
based on a global survey of researchers, who assigned characterization scores from 1 (poor) to 10 (extensive) for a sample of
genes based on major online resources. By evaluating the survey as training data, we developed a bioinformatics procedure to
assign gene characterization scores to all genes in the human genome. We analyzed snapshots of functional genome annotation
over a period of 6 years to assess temporal changes reflected by the increase of the average Gene Characterization Index.
Applying the Gene Characterization Index to genes within pharmaceutically relevant classes, we confirmed known drug targets
as high-scoring genes and revealed potentially interesting novel targets with low characterization indexes. Removing known
drug targets and genes linked to sequence-related patent filings from the entirety of indexed genes, we identified sets of low-
scoring genes particularly suited for further experimental investigation. Conclusions/Significance. The Gene Characterization
Index is intended to serve as a tool to the scientific community and granting agencies for focusing resources and efforts on
unexplored areas of the genome. The Gene Characterization Index is available from .
Citation: Kemmer D, Podowski RM, Yusuf D, Brumm J, Cheung W, et al (2008) Gene Characterization Index: Assessing the Depth of Gene
Annotation. PLoS ONE 3(1): e1440. doi:10.1371/journal.pone.0001440
INTRODUCTION
Elucidation of the function(s) for each human protein-encoding
gene has been a prominent challenge in biomedical research after
the completed deciphering of the sequence of the human genome.
Systematic characterization projects have been launched, ranging
from the ENCODE project for detailed genome annotation [1] to
the phenome projects to identify phenotypes generated by
mutations of human gene orthologs in model organisms [2–4].
These efforts were undertaken, in part, to evoke new insights into
the functions of uncharacterized genes revealed through the
successful sequencing of the human genome. At the level of basic
human curiosity, scientists are drawn to these uncharacterized
genes, for it is the deciphering of the functions of these genes which
offers the greatest potential to gain fundamental insights into novel
biological processes; to peer into the unknown. The therapeutic
and financial benefits associated with successful identification of
genes that are suitable targets for pharmaceutical research and
informative biomarkers for treatment selection stands as another
strong motivator.
The arsenal of the modern molecular researcher, when directed
at specific genes, can elucidate properties that offer glimpses of
underlying functions. In the laboratory we can determine specific
phenotypic effects of a gene when disrupted in model organisms,
where the encoded protein localizes within the cell, the spatio-
temporal coordinates of gene activity, the function in cells or
model organisms through biological assays, and further techniques
ad infinitum. To unleash these often expensive and time-consuming
studies, researchers (and funding agencies) are usually motivated
by preliminary glimmers of functional knowledge. However, with
the goal of comprehensiveness, attempts to explore genome
function in an unbiased manner have been made. In the
ENCODE project, undertaken by a portion of the global research
community to systematically annotate functions for 1% of the
human genome, a portion of the genome was selected for study for
the glaring absence of knowledge about the genes in the region [1].
The Allan Brain Atlas [5] places a premium on the systematic
study of expression in the mouse brain of uncharacterized genes.
In the pharmaceutical industries, gaining insights into the
functions of uncharacterized genes can offer a direct and
meaningful path to successful drug target identification.
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challenging to divide genes into classes depending on functional
knowledge and to extract sets of uncharacterized genes from the
genome. The characterization state of each gene exists in the eye
of the beholder; each scientist brings a distinct perspective to the
interpretation of the characterization status of a gene. While
scientists can select individual genes, judged as being scarcely
annotated based on available information in multiple data
repositories, no quantitative measurement of annotation status
exists widely applicable to sets of genes of particular interest to
further experimental study. However, previous studies have shown
that human opinion, based on specific sets of predictors, can be
quantified and predicted. In fact, researchers have surveyed the
perception of human beauty and developed computational
methods capable of accurately predicting consensus opinions by
collecting human ratings and developing machine learning
procedures based on those ratings [6,7].
With the goal of establishing a quantitative and universal system
for measuring the annotation status of human genes, we developed
the Gene Characterization Index (GCI), a bioinformatics
procedure to quantitatively assign a characterization score to each
human gene relying on collected opinions from the global research
community. In this report, based on training data derived from a
reference collection of genes with assigned characterization scores
from over 50 scientists worldwide, we constructed a classification
function that successfully predicts the characterization of human
protein-encoding genes. By applying the method to well-studied
classes of genes followed by comparison to the depth of annotation
in the Gene Ontology (GO) system [8], we confirmed the accurate
prediction of the level of functional characterization by the GCI.
At the genome scale, we integrated GCI values across all human
protein-encoding genes to determine the characterization status of
the human genome. We found that the progress made by the
research community to assign functions to human genes after the
release of the first draft of the human genome in 2000 was well-
reflected by an increase of the average GCI score across the
genome over time.
At a finer grain, analyzing classes of pharmaceutically relevant
gene families such as G protein-coupled receptors, nuclear
receptors and ion channels, we revealed specific characteristics
of the different groups and highlighted opportunities for the
identification of hitherto overlooked novel drug targets within
those therapeutically relevant protein families with potentially
important roles in the treatment of various diseases.
The GCI is the first automated method for quantitatively
assessing the extent to which each gene is annotated. By applying
the GCI scoring system on a genome scale, we identified a large
portion of the human genome, likely including groups of genes
with potentially interesting applications, essentially neglected by
the scientific community. By drawing attention to these groups of
weakly annotated genes, the GCI could help advance genome
characterization in an unbiased manner. Translated to the single
gene level, our scoring system is intended to help direct funding
agencies to these neglected areas and to guide the level of analysis
that should be funded. It serves as a resource for focusing
experimental efforts and can provide both computational and
laboratory scientists with opportunities to demonstrate the novelty
of current findings and the utility of new methods.
RESULTS
Implementation of the Gene Characterization Index
To create a quantitative method for assigning characterization
scores to each human gene, a representative reference collection of
scores for a subset of genes was required. This collection served
both as training data for determining predictive characteristics for
a perceived characterization state, as well as test data for
determining the reliability of the predictive methods generated.
To create a broadly representative method, the reference
collection of gene characterization scores was created through a
global survey of life sciences researchers with diverse scientific
backgrounds. We asked 52 scientists worldwide to assess a sample
of genes and assign a score within a 10-point scale, with 1
indicating a completely uncharacterized gene and 10 a gene that is
fully described. As the GCI directly reflects the scores obtained in
the survey, the survey is described in detail.
Reference gene definition and annotation source
Both for the survey and the ultimate production of the GCI, it was
necessary to define a reference set of human genes. Such lists could
be obtained from a variety of sources, each with unique
characteristics. In addition to a list of genes, we desired a system
that provided diverse functional annotations, as these gene
characteristics constituted the variables that could be evaluated
and quantitated by a scoring function. We selected the Entrez
Gene database [9] as an appropriate data source, as it met the
above-mentioned requirements and was expected to maintain data
quality with regular updates. To retroactively measure the
progress of human genome annotation, we further required a
gene annotation source providing access to releases over a multi-
year period. For this purpose, we selected the GeneLynx database
[10], as it was the most accessible system with resources
comparable to Entrez Gene for which annotations could be
obtained from an extended time period. Finally, we selected the set
of ‘‘training’’ genes from release 1.2 of the GeneLynx database
(June 2003) in a 2-stage process to insure a balanced represen-
tation of genes with diverse characteristics. We randomly chose an
initial set of 90 genes from the subset of genes for which cDNA
sequences were available in GenBank [11]. In addition, to insure
the inclusion of genes with minimal functional characterization,
we included 10 genes represented only by expressed sequence tags
(ESTs).
Evaluator ratings
To gather scores for the reference genes we developed a web-
based survey system. Each participating scientist was assigned 10
genes (including 1 EST-only gene) and asked to provide a
characterization value. An optional guide to scoring was made
available to the evaluators to assist in determining scores (see
online Supplementary Material). Each gene was assessed by
multiple biologists to allow the determination of an average score.
We sought at least 3 independent scores for each gene in the
reference collection. As genes were randomly assigned, the actual
number of responses per gene varied, with a minimum of 3 and an
average of 4.6. Supplementary Table S1 describes the complete
list of reference genes that was used in the survey together with
average evaluator ratings for each gene. Supplementary Figure S1
shows the distribution of evaluator ratings.
GCI classifier selection
Once we had collected evaluator ratings for the reference genes,
we set out to train a predictor from those ratings through the
application of machine learning procedures including linear
models (LM), regression trees (RT), neural nets (NN), support
vector machines (SVM) [12] and multivariate additive regression
splines (MARS) [13]. For the implementation of universal
predictors of gene annotation status, we first selected sets of gene
Gene Characterization Index
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indicated previously, we selected historical releases of the
GeneLynx database [10] as the source for annotation over an
extended time period. Similar to the more recent Entrez Gene [9],
GeneLynx provided links to a diverse array of online resources
with gene-specific information; these links were automatically
compiled from numerous systems. We treated the compilation of
resources for each gene as gene characteristics that could be
quantified. As those resources have changed over time, we
restricted the GCI training data to those resources that had been
recorded in GeneLynx since 2001. In addition to these core
GeneLynx annotations, we also considered gene-related articles
published prior to the survey; the article counts were based on
references in the Entrez Gene and SwissProt databases.
Initially, we compiled a total of 40 gene characteristics for the
reference genes (see Supplementary Table S2). We then created
each predictor vector by determining the total number of unique
attributes for each gene, followed by post-processing of each field,
including z-score normalization (see online Supplementary
Material). As a consequence, the list of 40 attributes was
subsequently reduced to 16 by removal of gene characteristics
not represented in all GeneLynx releases, and further by selection
of a single representative from highly correlated groups (Table 1
and 2). We considered attributes with a correlation of 0.7 or higher
similar, thus becoming candidates for removal.
Available attributes for use in the statistical model for defining
gene annotation state include single nucleotide polymorphisms
(SNPs) describing DNA sequence variations often linked to
disease, genomic sequences derived from GenBank [11], InterPro
[14], PRINTS [15] and PROSITE [16] domains assigning genes
to families, Gene Ontology (GO) annotations [8] using consistent
descriptions for gene function, reports in KEGG [17] integrating
genes into cellular pathways, associations in OMIM linking genes
to known diseases with a genetic component (http://www.ncbi.
nlm.nih.gov/omim/), RefSeq accessions [18] pointing to a gene’s
curated annotation level, SwissProt entries [19] providing
manually curated information on a gene’s protein product,
PubMed (http://www.pubmed.gov) literature references, PDB
[20] protein structure information, HomoloGene (http://www.
ncbi.nlm.nih.gov/HomoloGene/) linking genes to homologous
sequences in other species and descriptive annotations such as
gene name, symbol and functional description.
Model selection
Based on the performance observed and the clarity of the
underlying procedure, we selected a MARS model for the final
function. It is important to note that the selection of the statistical
approach had limited importance, as several methods performed
comparably well in the model validation step. The ultimate model
produced scores based on 6 attributes (Table 1). We explored
models using less attributes, but found that 6 attributes performed
best. Full documentation of the performance review and validation
can be found in the online Supplementary Material.
The MARS method assigned scores within +/21 of the average
reviewer score for 57% of reference genes and 81% of assigned
scores were within +/22 of the reviewer assigned scores (Figure 1).
However, for a few genes that scored greater than +/22 from the
mean, we conducted a manual review to assess the overall
annotation levels by enumerating available gene characteristics
possibly explaining the discrepancy between evaluator ratings and
computational predictions. For example, SOCS box-containing
WD protein SWiP-1 (WSB1) (Entrez Gene ID 26118), rated at 2.5
but was predicted at 5.3. This gene presented a moderate number
Table 1. Classification model attributes used by the MARS
model.
......................................................................
Attribute Description
GBACC GenBank sequences
INTERPRO Interpro domains
KEGG KEGG pathways
MEDLINE MEDLINE references in Entrez Gene
OMIM OMIM references
SPID SwissProt protein links
doi:10.1371/journal.pone.0001440.t001
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Table 2. Additional available classification model attributes.
......................................................................
Attribute Description
DBSNP Single nucleotide polymorphisms
ENSEMBL EnsEMBL transcripts
GO Gene Ontology terms
HOMOLOGENE Non-human homologous sequences
NAME Gene symbols and alias symbols
PDB PDB protein structures
PRINTS PRINTS protein fingerprints
PROSITE Prosite references
REFSEQ RefSeq sequences
TREMBL TrEMBL links
doi:10.1371/journal.pone.0001440.t002
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Figure 1. GCI Model Cross-validation Performance. GCI Predictor
Performance–Leave-One-Out cross-validation results for the final GCI
predictor model utilizing the MARS method on z-score normalized data.
The X-axis displays average evaluator assigned scores, while the Y-axis
displays the predicted scores for each gene in the leave-one-out cross
validation analysis (the score assigned when the gene was not included
in the training data). As observed, the MARS model can assign scores
greater than 10 (in all further analysis such scores are rounded down to
10).
doi:10.1371/journal.pone.0001440.g001
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domain-specific annotations and therefore, was scored low by
human evaluators. However, inclusion of WSB1 in the KEGG
database of cellular pathways, the OMIM database of disease
associations, the SwissProt protein database, as well as the
presence of a number of SNPs suggested a curated level of
functional annotation. As a consequence, we judged that the
predicted score more accurately reflected the functional under-
standing of the gene.
Performance of the Gene Characterization Index
To assess the capacity of the GCI scoring model to successfully
predict gene annotation levels, we integrated characterization
scores across all predicted human genes and further compared
those scores to information content from the Gene Ontology (GO)
gene annotation system [8].
Genome-scale scoring and temporal annotation
changes
Since the release of the first draft of the human genome sequence
in 2000, concerted efforts of the scientific community have resulted
in the successful delineation and functional annotation of a large
body of predicted human genes. We reasoned that, following
genome evolution over the years since its release, we could follow
and quantify the expansion of functional knowledge via an
increase in the average GCI score over time. To compare
successive versions of the human genome, we applied the final
GCI scoring model to all genes present in either the Entrez Gene
database [9] for recent genome releases, or in the GeneLynx
database [10] for historical genome versions.
The histogram in Figure 2 shows the distribution of GCI scores
across all human genes taken at 3 different time points. In the
earliest version, 64% of all genes (20475 of 31987 genes) clustered
at the bottom of the scale with scores lower than 2.5, and less than
3% (885 genes) scored at 7.5 or higher, reflecting the scarce overall
annotation level of the human genome. Successive genome
releases showed an important decrease in the low-scoring group
of genes with 30.9% of scores (10308 of 33410 genes) under 2.5 for
the latest release in September 2007. Also apparent from the
histogram was the steady increase in high-scoring genes over time.
The portion of genes scoring above 7.5 rose from merely 2.8%
(885 of 31987 genes) in May 2001 to 8.3% (2588 of 31096 genes)
in April 2004 reaching 15.8% (5286 of 33410 genes) in the latest
release. Overall gene numbers fluctuated between successive
genome releases due to changing genome annotations and
transcript-to-gene mappings. To provide some perspective to the
reader, we assembled a subset of the highest and lowest scoring
genes from the September 2007 release presented in Tables 3 and
4.
Qualitative adaptation of scoring model
To qualitatively assess the increase in gene characterization over
time, we analyzed contributions of different annotation sources
assembled in Entrez Gene and GeneLynx to rising gene
annotation levels. We counted entries for each attribute selected
by the MARS model. Analyzing annotation changes between July
2006 and September 2007, it became apparent that the increase in
the number of PubMed references largely dominated all other
attributes, and thus, publications could be considered the most
important contributor to the recent advancement of gene
annotation levels (Table 5). In addition to publication in peer-
reviewed journals, recent expansion of the KEGG database of
cellular pathways contributed moderately to improved annotation.
While new disease associations recorded in the OMIM database
and new SwissProt entries contributed to increased annotation
levels, there was a decrease in the number of protein domain
family associations reported in InterPro likely reflecting a change
in genome annotation procedures.
After investigating characteristics of the more recent genome
annotation, we analyzed earlier developments directly following
the release of the first genome sequence drafts. Historical
annotation changes were reflected by changing attributes selected
by the MARS model in the GeneLynx database. While there had
been a steady increase in the number of PubMed references across
all time points, earlier releases were essentially marked by an
increased association of cDNAs-to-genes and the designation of
official gene names and symbols. Other characteristics of
functional gene annotation were the inclusion of SNPs, increases
in Gene Ontology annotations, InterPro domains, KEGG
pathways, and OMIM disease associations.
Comparison to Gene Ontology annotation levels
The Gene Ontology (GO) project is an effort to standardize gene
descriptions using a predefined vocabulary of functional terms [8],
and GO terms are now widely used to functionally annotate genes
and their protein products [21]. GO is a highly curated system that
uses 3 structured ontologies to describe genes in terms of their
associated molecular function, biological process and cellular component.A s
gene annotation levels deepen, the hierarchy of specialized GO
terms extends, describing the gene in greater detail. Functional
comparison of sequences annotated with GO terms can be
performed based on semantic similarity measures like the ones
developed by Resnik [22].
For genes drawn from the latest genome release (September
2007) with GO annotations, we extracted the maximum
information content for each gene by using Resnik’s similarity
measure reflecting the granularity of the GO terms assigned to a
given gene. We then compared these raw information content
scores to the GCI scores obtained with our scoring model using
Pearson correlations. For the comparisons, we selected equal
numbers of genes from each bin of GCI scores (e.g. 1–1.4, 1.5–2.4,
etc.; see Figure 2 for bins) and calculated overall correlations.
Comparing all GCI scores to the GO molecular function category
Figure 2. Genome-wide GCI Score Distribution. Histogram displaying
the frequency of scores observed in the analysis of genes at 3 different
time points after the release of the first draft of the human genome
sequence. Genes based only on predictions and/or EST sequences have
been removed (,3000 genes in 2007 data).
doi:10.1371/journal.pone.0001440.g002
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of 0.59. We also combined bins into larger groups representing
increasing annotation levels (low ,2.5, medium low 2.5–4.9,
medium high 5.0–7.4 and high 7.5–10.0) and examined
differences between GCI and GO (Figure 3). Genes with higher
scores agreed best with the Resnik scores for GO molecular functions,
while genes with low scores showed weaker correspondence. No
strong correlations were observed for GO biological process and
cellular compartment categories (data not shown). The positive
correlation between Resnik scores of GO molecular function and
GCI scores further validated our automated scoring model as an
accurate reflection of the depth of gene annotation levels.
Application of the Gene Characterization Index
Analysis of drug target gene families Using the predictions of
functional gene annotation levels from the GCI scoring system, we
investigated the properties of annotation for a variety of gene sets
relevant in medicine and drug development. Over the past few
decades, 3 gene families have stood out as the most common drug
targets: G protein-coupled receptors (GPCRs), nuclear receptors
(NRs), and ion channel proteins (ICs) [23]. We extracted all gene
members of these families from appropriate resources and, using
DrugBank as a resource for drug data and protein target
information [24], divided them into known drug targets and
non-drug targets. By analyzing each family for its annotation
Table 3. Sets of genes with extreme characterization scores: sampling of well-characterized genes.
..................................................................................................................................................
Gene Name Symbol GCI Gene ID Description
Lamin A/C LMNA 10.0 4000 Lamin-A/C (70 kDa lamin) (Renal carcinoma
antigen NY-REN-32)
Collagen, type II, alpha 1 COL2A1 10.0 1280 Collagen, type II, alpha 1 (primary osteoarthritis,
spondyloepiphyseal dysplasia, congenital)
Phosphatase and tensin homolog PTEN 10.0 5728 Phosphatase and tensin homolog (mutated in
multiple advanced cancers)
Tumor protein p53 TP53 10.0 7157 Cellular tumor antigen p53 (Tumor suppressor
p53) (Phosphoprotein p53) (Antigen NY-CO-13)
Fibroblast growth factor receptor 2 FGFR2 10.0 2263 Fibroblast growth factor receptor 2 (bacteria-
expressed kinase, keratinocyte growth factor
receptor, craniofacial dysostosis 1, Crouzon
syndrome, Pfeiffer syndrome, Jackson-Weiss
syndrome)
Titin TTN 10.0 7273 Titin (EC 2.7.11.1) (Connectin)
(Rhabdomyosarcoma antigen MU-RMS- 40.14)
Peroxisome proliferator-activated receptor
gamma
PPARG 10.0 5468 Peroxisome proliferator-activated receptor
gamma (PPAR-gamma)
Paired box 6 PAX6 10.0 5080 Paired box protein Pax-6 (Oculorhombin)
(Aniridia type II protein)
Melanocortin 1 receptor MC1R 10.0 4157 Melanocortin 1 receptor (alpha melanocyte
stimulating hormone receptor)
V-Ki-ras2 Kirsten rat sarcoma viral oncogene
homolog
KRAS 10.0 3845 GTPase KRas precursor (K-Ras 2) (Ki-Ras) (c-K-ras)
(c-Ki-ras)
doi:10.1371/journal.pone.0001440.t003
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Table 4. Sets of genes with extreme characterization scores: sampling of scarcely characterized genes.
..................................................................................................................................................
Gene Name Symbol GCI Gene ID Description
KIAA1833-like 1.5 377711 LOC377711 KIAA1833-like
LOC730919 1.5 730919 Hypothetical protein LOC730919
Family with sequence
similarity 24, member A
FAM24A 1.5 118670 FAM24A family with sequence similarity 24, member A
Chromosome 1 open reading
frame 192
C1orf192 1.5 257177 C1orf192 chromosome 1 open reading frame 192
LOC284428 1.5 284428 LOC284428 similar to methyl-CpG binding domain protein 3-like 2
LOC388910 1.5 388910 RP3-474I12.5 hypothetical LOC388910
Family with sequence similarity
90, member A3
FAM90A3 1.5 389611 FAM90A3 family with sequence similarity 90, member A3
LOC400723 1.5 400723 Hypothetical LOC400723
LOC400856 1.5 400856 Hypothetical gene supported by AK123815
LOC440776 1.5 440776 Hypothetical LOC440776
doi:10.1371/journal.pone.0001440.t004
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potential opportunities to study neglected members of these
biologically relevant gene classes, as well as to discover new drug
targets.
G protein-coupled receptors GPCRs, targeted by nearly
one third of currently marketed drugs [23], are diverse in structure
and function, and, with their broad evolutionary conservation, are
considered the oldest cellular machineries devoted to signal
transduction. From the G Protein-Coupled Receptor Data Base
(http://www.gpcr.org/) [25] and GO annotations, we extracted a
set of 750 GPCRs for further analysis. Applying annotations from
DrugBank, we divided the set into GPCRs of FDA-approved drug
targets (79) and receptors previously not targeted by
pharmaceuticals (671) and applied the GCI scoring system. As
apparent from Figure 4A, over 80% of drug target GPCRs
presented deep annotation levels and scored between 8.5 and 10.0.
This group included highly relevant drug targets such as the
angiotensin receptor (AGTR1), serotonin receptor (HTR2A), and
endothelin receptor (EDNRB). However, analyzing GPCRs not
targeted by small molecule drugs revealed that the majority had
remained weakly characterized with GCI scores for over 60% of
genes ranging from 1.5 to 5.4 highlighting opportunity for further
study and development of new targets within this highly relevant
gene family. For example, G protein-coupled receptor 137C
(GPR137C, Entrez Gene ID 283554, GCI=3.23), a weakly
annotated GPCR, is linked to a single PubMed publication
associating the gene’s transcription to a gastric cancer gene
expression profile [26]. Another example is the 7 transmembrane
helix receptor LOC440683 (Entrez Gene ID 440683) scoring at
2.16 with reported rhodopsin-like receptor activity and no further
functional information associated. It should be noted, however,
that the group of low-scoring GPCRs could be partly accounted
for by the inclusion of olfactory receptors, a subclass with limited
therapeutic potential. Comparing the non-drug target group of
GPCRs with the GenBank patented sequence repository showed
that 537 genes (80%) had patents associated with them.
Nuclear receptors Based on GO annotations and the
Nuclear Receptor Database (http://www.receptors.org/NR/)
[27], we extracted 50 NRs for further analysis. This second
largest group of current drug targets functions as ligand-activated
transcription factors and regulate core cellular processes such as
cell growth and differentiation, inflammatory responses and
metabolism. Their important role in physiology and the ability
to regulate their functional activity with synthetic small molecules
has rendered this gene family a favorite target for drug discovery
[28]. Subjecting NRs to the same analysis as GPCRs, we found
that 22 of 23 drug target NRs presented GCI scores of 7.5 and
above (Figure 4A). Similarly, the distribution of GCI scores for all
27 non-targeted NRs was high (average GCI=7.8) reflecting the
intense scrutiny given to these proteins. Across all NRs, a single
gene obtained a low GCI score at 2.9. This gene (Entrez Gene ID
55566), coding for the estrogen receptor-like p65 protein and
linked to colorectal cancer through 2 PubMed publications, lacked
additional functional annotation making it a particularly
interesting candidate for further study. As shown for GPCRs,
Table 5. Individual contribution of attributes to rising
annotation levels.
......................................................................
Attributes July 2006 Sept 2007 Change (%)
MEDLINE 229728 338417 +47.3
GBACC 190077 227822 +19.9
KEGG 8444 9618 +13.9
OMIM 14135 15586 +10.3
SPID 14306 15631 +9.3
INTERPRO 51087 44759 212.4
(GBACC=GenBank accession, SPID=SwissProt identifier).
doi:10.1371/journal.pone.0001440.t005
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Figure 3. Resnik Scores for Depth of GO Gene Annotation Correspond with GCI Scores. The Resnik score describes the granularity of annotations
attached to each gene. There is an overall Pearson correlation of 0.6 between GCI and Resnik scores. The distribution plot shows the distribution of
Resnik scores for ranges of GCI scores.
doi:10.1371/journal.pone.0001440.g003
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associated with them.
Ion channels ICs constitute the third major class of current
drug targets including ligand- and voltage-gated ion channels. The
family of ligand-gated ion channels (LGICs) comprises several
superfamilies and their physiological activity controls information
flow in the brain, thus becoming a relevant class of targets for
drugs treating disorders such as epilepsy and anxiety [29]. From
the Ligand-Gated Ion Channel database (http://www.ebi.ac.uk/
compneur-srv/LGICdb/LGICdb.php) [30] we extracted 66
genes, of which 21 coded for FDA-approved drug targets.
Comparable to NRs, 86% of drug target LGICs scored above
7.5, whereas the distribution of GCI scores for non-drug target
LGICs was more widely distributed with 38% of genes scoring
below 7.5 (Figure 4A). Several low-scoring, non-drug target LGICs
coded for weakly annotated subunits of well-known receptor
complexes: the alpha 4 subunit of the glycine receptor (GLRA4,
Entrez Gene ID 441509, GCI=1.5), the rho3 subunit of the
gamma-aminobutyric acid (GABA) receptor (GABRR3, Entrez
Gene ID 200959, GCI=3.3), and several subunits of the type 3
Figure 4. A. Distribution of GCI Scores for Genes in Selected Protein Families and Classes. 750 G Protein-Coupled Recptors: 79 DTG, 671 NDTG; 50
Nuclear Receptors: 23 DTG, 27 NDTG; 66 Ligand-Gated Ion Channels: 21 DTG, 45 NDTG; 111 Potassium Ion Channels: 14 DTG, 97 NDTG. B. Genome-
wide GCI Score Distribution for Drug Targets, Patented and All Other Genes. Based on genome release July 2006: 1095 drug targets, 14237 patented,
14913 non-target, non-patented genes. 10867 non-targeted, non-patented genes were highly uncharacterized with GCI scores ,3.5.
doi:10.1371/journal.pone.0001440.g004
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PLoS ONE | www.plosone.org 7 January 2008 | Issue 1 | e1440receptor for 5-hydroxytryptamine (serotonin). It should be noted
that the pool of non-drug target LGICs may include subunits of
receptor complexes already targeted by small molecule
compounds, as illustrated by the GABAA receptor gamma 2
subunit (GABRG2), with a GCI score of 10.0 and no current
records in DrugBank. The gene’s mutated isoforms have been
implicated in epilepsy [31] and, as a subunit of the type A GABA
receptor, this gene is part of a protein complex heavily targeted by
pharmaceuticals. However, weakly annotated subunits of already
targeted protein complexes may present opportunities for the
development of novel drugs targeting new sets of targets within
protein complexes with known therapeutic potential. As for
GPCRs and NRs, the large majority of non-drug target genes
(89%) were associated with patents.
Another important class of ICs, Potassium Ion Channels (KICs),
associated with action potentials and intercellular signaling,
perform a wide variety of functions in both excitable and non-
excitable cells and thus, have been recognized as potential drug
targets [32]. From the KChannelDB (http://www.receptors.org/
KCN/), we extracted 111 KIC genes, 14 of which were targeted
by small molecule drugs according to DrugBank. Applying the
GCI scoring system to the drug targets, we observed that 9 of 14
KICs obtained scores at 7.5 and above, and that no gene scored
below 5.5 (Figure 4A). The analysis of the non-drug target KICs
yielded a somewhat different distribution with almost half of the
genes (47%) scoring at medium high levels (5.5–7.4), and an
important portion (22%) in the range of moderate to weak
annotation levels (,5.5). Several of these moderately annotated
genes were members of a group of potassium channels containing
tetramerisation domains. Non-targeted KICs, and thus interesting
for further study, included the potassium channel subfamily T
member 1 (KCNT1, Entrez Gene ID 57582, GCI=4.8) and
member 2 (KCNT2, Entrez Gene ID 343450, GCI=5.0), the
potassium channel subfamily K member 18 (KCNK18, Entrez
Gene ID 338567, GCI=4.2), the potassium voltage-gated channel
shaker-related subfamily member 7 (KCNA7, Entrez Gene ID
3743, GCI=5.7), and the KCNE1-like membrane protein
(KCNE1L, Entrez Gene ID 23630, GCI=6.4). Similar to the
rates for other drug target gene families examined, we observed
that 88 of 97 (91%) non-drug target KICs were associated to
patents in GenBank.
Genome-wide analysis of drug target and patented
genes To expand the analysis of GCI distributions to the
whole genome, we extracted the entire set of drug targets from
DrugBank (1095 proteins) and all patented genes reported in
NCBI’s patent nucleotide sequence database (14295 genes).
Figure 4B illustrates the genome-wide distribution of GCI scores
for the different gene classes. Similar to the distribution pattern
observed for specific drug target gene families, drug target genes in
the genome clustered at the high end of the scoring scale with over
75% having GCI scores above 7.5. Patented genes were scattered
across the range of scores with a smaller fractions at the low end
(i.e., 1.9% receiving scores ,2.4). Removing all drug target and
patented genes from the genome, we applied the GCI scoring
model to the remaining 14913 genes. Tellingly, over 70% of the
non-patented non-target genes were highly unexplored with GCI
scores ,3.5. The remainder of genes was distributed across the
entire scale with decreasing numbers for increasing scores.
Effect of patent filing on gene characterization Since
applications for patents on DNA sequences became common
practice in the early 1990’s [33], critics have raised a number of
objections against the patenting of biological material. The debate
has remained vivid to the current day [34,35]. The question
whether, and to what extent, patenting of genes impacts academic
science has remained a topic of controversy. To follow functional
annotation progress of patented versus non-patented genes since
2001, we applied the GCI scoring system to all patented and non-
patented genes and followed the fate of the different groups up to
September 2007, 6 years after the release of the first draft of the
human genome sequence. From NCBI’s patented sequence
database, we extracted 11278 patented genes, applied the GCI
scoring system based on both GeneLynx release 0.9 (May 2001)
and Entrez Gene release September 2007 and compared the GCI
score distribution for the 2 time points. In the same way, we
extracted 20867 non-patented genes from GeneLynx 0.9 and
19331 non-patented genes from Entrez Gene September 2007 and
compared the score distributions between the 2 genome releases. It
should be noted that there have been fluctuations in the mappings
of cDNAs to genes in successive genome releases accounting for
the slight variations in the number of genes in the different groups
between 2001 and 2007. For patented genes in 2001, 93% of GCI
scores spanned across the low to medium part of the scale
(GCI,7.5), with merely 7% clustering at the high end (GCI$7.5)
(Figure 5). In 2007, however, the centre of the distribution was
shifted from low (GCI=1.5–2.4) to medium high scores
(GCI=6.5–7.4), with over 36% of genes ranking above 7.4. In
2007, there were only 1.3% of patented genes left scoring below
3.5. By dividing the genes into bins, it became apparent that over
40% of patented genes had climbed up the scale from the low GCI
bin, with the highest increase for the high GCI bin (Table 6).
The evolution for the GCI distribution for non-patented genes
was markedly different. As illustrated in Figure 5, in 2001 over
90% of all non-patented genes clustered at scores below 3.5, with
less than 1% reaching the high end of the scale (GCI$7.5). In
September 2007, this distribution had not notably changed with
over 75% of genes remaining at the low end of the scale
(GCI,3.5). The majority of genes that had left the low GCI bin
had moved to the medium GCI bin, and not to the high GCI bin
as observed for patented genes (Table 6). Also, a fraction of the
genes originally in the low score bin had been removed all together
(1535 genes), likely due to genome reannotations.
Figure 5. Evolution of Patented versus Non-Patented Genes between
2001 and 2007. Histogram presenting substantial differences in
annotation progress between patented and non-patented genes.
Fluctuating gene numbers due to changes in genome annotations
and transcript mappings.
doi:10.1371/journal.pone.0001440.g005
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Users may access the GCI at http://www.cisreg.ca/gci/, where
they can search for the functional characterization level of their
favorite gene, browse for genes with specific annotation levels,
choose random genes and further explore the system. After
searching with the gene name, Entrez Gene ID or free text, the
GCI scoring system returns the GCI score for the searched gene,
as well as links to various data sources underlying the computed
score (Figure 6). It is also possible to search for genes in bulk,
where the GCI scoring system accepts lists of genes with Entrez
Gene IDs and returns scores for all genes from the list. For
scientists interested in comparing their own perception to the
automated scores, they may perform a blinded test. A randomly
selected set of 10 genes will be displayed and the user may assign
their own scores. After assignments are submitted, a comparison
report is generated. Scores submitted through this process will be
used as training data for future releases of GCI (to reflect temporal
shifts in human perception of what constitutes a well-characterized
gene). Finally, users may download the entire set of scores, as well
as access the data and Supplementary Material described in this
manuscript.
DISCUSSION
We have introduced a novel bioinformatics procedure to
quantitate the functional characterization of each protein-
encoding human gene. Based on a reference collection of
characterization scores assigned by diverse life scientists, we
trained a classification function to predict scores depending on
functional annotations in the Entrez Gene database. Using a
MARS classifier that performed well in cross-validation, we were
able to assign characterization scores to all human genes.
As a first assessment of the performance of the GCI scoring
system, we assigned scores to all accessible genes in consecutive
releases of the human genome and followed GCI score distribution
and attribute selection of the MARS model. We could show that
the GCI scoring function mirrored an increase in genome
annotation performed by the research community through a shift
of score distributions to deeper annotation levels. The changing
weight assigned by the GCI scoring system to different attributes
over time reflected befittingly the evolution of the human genome.
While early releases were marked by predictions of fluctuating
numbers of genes, whose active transcription could only be
confirmed for a fraction, the association of cDNAs with predicted
genes was an important factor in the genome characterization
effort. Also, the rate of gene discovery was high, and the
classification of novel genes according to sequence motifs and
domains into protein families was an important step in inferring
functional information. Unlike this early phase of the genome era,
the sequence quality of later releases improved dramatically with
the official closure of the human genome project in April 2003
[36]. As a consequence, gene numbers became more stable
leveling off around 25000 human genes [37]. Most of these genes
were confirmed by RNA transcripts and basic functional
information existed for many of them. Later advancements in
gene annotations captured by the GCI scoring model, therefore,
were defined by deeper levels of functional characterization,
especially in the form of scientific publications describing
individual genes and curated functional knowledge in databases
such as KEGG, OMIM and SwissProt.
In a second assessment of model performance, we showed that
GCI annotation levels correlated well with Gene Ontology terms
of molecular function, with no correlations observed for the biological
process and cellular component categories. This observation revealed
that GCI scores, which are based on specific gene attributes,
referred to unambiguous cellular functions such as binding,
receptor, transporter or enzyme activities rather than higher-
ranking biological processes or cellular components of a gene’s
activity. It also became apparent that the level of functional
annotation captured by the GCI scoring model increasingly
paralleled GO molecular function hierarchies the deeper a gene’s
functional characterization reached.
Applying the GCI to 3 major protein families of current drug
targets, we presented each family’s overall annotation status and
pointed to potential candidates for further investigation within
these highly ‘‘druggable’’ gene classes. Most likely due to their
great sequence diversity rendering homology searches across
species more difficult, the sequencing of the human genome had
revealed many new GPCRs. In our survey, this gene class
produced the largest fraction of weakly characterized genes leaving
ample opportunity for further investigations. The small protein
family of nuclear receptors, to the contrary, displayed less room for
development with the majority of genes deeply characterized,
possibly due to their small number and easy accessibility compared
to membrane-bound receptors. Even though both families of ion-
channel genes lacked genes remaining at the very low end of the
characterization scale, there still was prospect of novel therapeutic
applications owing to hitherto untargeted subunits of target
protein complexes and family members regulating protein
structure. Given that over 50% of current drugs target G
protein-coupled receptors, nuclear receptors and ion channels
and that the majority of new drugs target precedent domains, to
tap the full potential of these families by highlighting any neglect
may be important for the advancement of therapeutic approaches
by small molecule drugs.
As opposed to the common belief that corporate interest had a
negative impact on scientific progress in particular through the
filing of patents on genes and gene-derived sequences, we observed
that patenting did not hamper gene characterization. As already
apparent from the analysis of ‘‘druggable’’ genes both within
specific gene classes (Figure 4A) and the whole genome (Figure 4B)
and based on the fact that the large majority of drug target genes
(86%) was protected by patents, drug targets mostly clustered at
the high end of the characterization scale. Analyzing annotation
progress of patented versus non-patented genes across an extended
time period unveiled an association of functional characterization
and gene patenting. While it is probable that patenting was biased
towards proteins with detectable protein domains now recorded by
genome annotation engines, the increase in the patented gene
scores was heavily driven by new publications. The scientific
community seemed to have been focusing on patented genes in
their efforts to study the molecular function of genes.
Another capacity of the GCI scoring system is to identify areas
of ‘‘neglect’’ within either groups of genes or the whole genome.
Following the annotation status of all human genes since the
Table 6. Change in GCI score distribution of patented versus
non-patented genes between May 2001 and September 2007.
......................................................................
GCI bins Patented Non-patented
% (genes*) % (genes*)
1.0–3.4 241.3 (24653) 215.4 (24371)
3.5–7.4 +9.7 (+1226) +12.3 (+2247)
7.5–10.0 +31.6 (+3642) +3.1 (+588)
*Unbalanced numbers due to gene mapping changes between 2001 and 2007
doi:10.1371/journal.pone.0001440.t006
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PLoS ONE | www.plosone.org 9 January 2008 | Issue 1 | e1440release of the first draft of the human genome, we identified a large
pool (,14500) of genes essentially uncharacterized to the present
day. These genes have minimal functional annotation with scores
below 3.5 and represent over 75% of genes neither protected by
patents nor targeted by small molecule drugs. These findings clearly
illustrate the inestimable potential still hidden within the human
genome in that a considerable portion of genes are shrouded in
darkness, awaiting attention and functional elucidation.
Figure 6. Screenshot of GCI Web Page. Example of Calmodulin-like protein 6 returned by GCI search engine with gene-specific GCI score and links to
data sources.
doi:10.1371/journal.pone.0001440.g006
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PLoS ONE | www.plosone.org 10 January 2008 | Issue 1 | e1440Using the GCI scoring system to delineate groups of scarcely
annotated genes could aide decision-making for the allocation of
research funds. Current research funds are distributed in large part
on the basis of extensive preliminary data; there is great reluctance
to fund projects deemed as ‘‘high-risk’’ which would include the
study of uncharacterized genes. As indicated in this report, vast
genome areas have remained unexplored. The availability of GCI
scores could direct resources to these neglected areas. During
grant reviews, GCI could help identify proposals of greater novelty
(a weighting factor for many funding groups) by serving as a
novelty measure.
The GCI produced by this study represents a novel direction in
bioinformatics research. By classifying genes based on a qualitative
score assigned by humans, it represents opinion research. The
existing GCI scores reflect the state of opinion at the time of the
survey. For instance, in 19 cases evaluators assigned a score of 10
to a gene. While this perceived high characterization reflects the
most deeply studied genes, it is unlikely that future scientists would
view our present state of gene knowledge as complete. As research
advances, the perspectives of scientists will without doubt change
and our expectations for the required properties of genes to be
considered characterized will become more stringent. In addition,
over time, the available types and sources of data change.
Therefore, the GCI scoring function will require periodic updating
to reflect available annotation resources and changing opinions of
researchers. Besides, it would be desirable in the future to develop
GCI scores for model organism genes to determine how the
characterization of orthologs of human genes influences the
progression of the GCI. The GCI scoring system could serve as an
important tool for focusing efforts and resources on the study of
weakly characterized genes.
METHODS
Analysis of results from survey
As described, the survey of 52 scientists produced an initial
collection of scores for the 100 reference genes with an average
of 4.6 scores per gene. We implemented quality control
procedures to identify unusual results. For each respondent, we
compared the set of assigned gene scores to the mean score for
each gene using a Pearson correlation coefficient. Scores from 3
reviewers with correlation scores more than 2 standard
deviations from the average correlation score were excluded
from the reference collection (Supplementary Figure S2). As an
additional quality control procedure, we reviewed individual gene
scores for unaccounted deviations from the average. No
individual gene or reviewer appeared particularly unusual after
this final review, although we identified 3 scores as outside the
observed range of scores and thus excluded them. After removal
of outlying scores, an average of 4.2 scores per gene remained in
the reference set.
Model selection
We used the R Statistical Language (http://www.r-project.org/)
to implement all gene characterization score prediction methods.
Initially, we conducted a performance review of linear models
(LM), regression trees (RT), neural nets (NN), support vector
machines (SVM) and multivariate additive regression splines
(MARS). All of the approaches exhibited similar and adequate
accuracy for GCI scoring, as assessed by cross-validation.
Model validation
We verified the quality of the model by a Leave-One-Out (LOO)
cross-validation method. For each of the 100 genes, we
constructed a model with the other 99 genes and compared the
score assigned by the model to the excluded gene to the reference
score. The Root Mean Square (RMS) error provided an overall
performance measure. We tested a number of data transforma-
tions including binary values, binned, log, maximum value
normalization, and z-score normalization. Of the 5 model
frameworks tested, SVM and MARS performed best. The SVM
model failed to assign scores across the entire scale and was
therefore set aside. For the MARS model a range of values for the
parameters ‘‘degree‘‘ (range 1 to 3) and ‘‘penalty‘‘ (range 0 to 6)
was tested. We presented the best model with degree 1 and penalty
of 1. The MARS procedure selected a subset of available attributes
to optimize the fit to training data. The ‘‘degree’’ controlled the
maximum number of splines that could be used for each attribute
across the range of the expected predictions, and the ‘‘penalty’’
was used to decide if an additional attribute should be utilized in
constructing the model. Increasing the ‘‘penalty’’ reduced the
number of attributes used by the final model. Attributes utilized in
the best MARS model are shown in Table 1. A complete
documentation of the model validation is provided in the online
Supplementary Material.
Calculation of Resnik scores
The usage of GO terms varies considerably–a rather general GO
term may be associated with many genes and is therefore not very
explicit, whereas a very detailed term will only be used for few
genes for which the specific function may be applied. Resnik self-
similarity scores for the GO molecular function taxonomy provide a
numerical measure for the depth of GO annotations for individual
genes. The Resnik self-similarity score is based on the lowest (most
detailed) parent node in the GO annotation hierarchy for a
specific gene by extracting the maximum information content of
the node [22]. The information content is linked to the probability
of observing the GO term based on counting how many times the
GO term appears in annotated gene products which is reported
regularly by the GO Consortium [38]. The GOSim 1.0.2 package
[39] was used to compute the scores in the R 2.5.1 statistics
package (http://www.r-project.org/).
Analysis of patented genes
We screened NCBI’s patented nucleotide sequence database for
human transcripts and matched a total of 14295 GenBank
accessions to patent records. To assess GCI score distributions
across several years, we mapped the patented genes to either
GeneLynx or Entrez Gene identifiers and applied the GCI scoring
model based on successive GeneLynx [10] and Entrez Gene [9]
releases.
Gene mappings between GeneLynx and Entrez
Gene
For all analyses of datasets comparing data from the latest
GeneLynx release (April 2004) and earlier with datasets from more
recent Entrez Gene releases, mappings between GeneLynx and
Entrez Gene identifiers were performed via EnsEMBL [40] gene
and transcript intermediates. Due to substantial changes in gene
mappings between May 2001 and September 2007, only 16494
individual genes could be directly mapped between GeneLynx and
Entrez Gene with a bias towards genes with more extensive
functional annotation (see Supplementary Material).
SUPPORTING INFORMATION
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